Glonghui, May 9 | Lyon published a research report showing that BeiGene's sales for the first quarter of fiscal year 2024 increased 67.9% year-on-year, and its performance exceeded market expectations. The bank believes that sales of BTK inhibitors independently developed by BeiGene are still the main driving force for its performance, with sales of related inhibitors increasing by 131.1% year on year. According to the bank's statistics, the market share of these inhibitors in the US has increased to 24.1%, while the market share for the third quarter and fourth quarter of last year was 19.1% and 21.2%, respectively. The bank also believes that the progress of the company's BCL-2 and BTK CDAC products this year is worth paying attention to. Lyon adjusted its performance forecast for BeiGene and raised its target price for H shares from HK$138.5 to HK$139.7, reaffirming its “buy” rating.